| P/E (FY) | — | Sales (TTM) | $776.8M |
| Earnings (TTM) | -$29.0M | ROE | −3.68% |
| Net Margin | −5.36% | ROIC | −5.18% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 2.52% |
Supernus Pharmaceuticals is a biopharmaceutical company developing and commercializing treatments for central nervous system diseases in the United States. Its products include Qelbree, a non-stimulant for ADHD; GOCOVRI for dyskinesia in Parkinson's disease; Oxtellar XR and Trokendi XR for epilepsy and migraine prophylaxis; APOKYN for off episodes in advanced Parkinson's; and XADAGO for Parkinson's disease.
| Market Cap | $2.77B | Trading Days | 1586 |
| 52W High | 59.68 |
| 52W Low | 32.83 |
| % Off High | −20.02% |
| YTD | −3.96% | 1Y | 42.86% |
| 3Y | 56.90% | 5Y | 70.34% |
| Since incept. (ann.) | 17.42% |
Reportable 100%
| Ann. Volatility (1Y) | 36.96% | Ann. Volatility (3Y) | 36.24% |
| Sharpe (1Y) | 1.16 | Sharpe (3Y) | 0.61 |
| Max Drawdown (1Y) | −23.54% | Max Drawdown (3Y) | −30.96% |
| Beta (3Y, vs SPY) | 0.70 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| IRON | Disc Medicine, Inc. | $2.85B | — |
| MBX | MBX Biosciences, Inc. | $2.86B | — |
| CUE | Cue Biopharma, Inc. | $2.87B | — |
| ATAI | AtaiBeckley Inc. | $2.64B | — |
| IMNM | Immunome Inc. | $2.63B | — |
| TRVI | Trevi Therapeutics, Inc. | $2.62B | — |
| GRTX | Galera Therapeutics, Inc. | $2.61B | 25.4 |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.56B | — |
| NRIX | Nurix Therapeutics, Inc. | $2.51B | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.45B | 13.2 |
| IDYA | IDEAYA Biosciences, Inc. | $3.18B |
| VERA | Vera Therapeutics, Inc. | $2.39B | — |
